Changes in False Claims Act Enforcement: Impact on Insurance and Healthcare
Understanding Changes in False Claims Act Enforcement: Implications for Insurance and Healthcare Industries
The False Claims Act (FCA) plays a pivotal role in federal anti-fraud efforts, particularly in the insurance and healthcare sectors. In fiscal year 2024, this essential legislation facilitated the recovery of nearly $3 billion through judgments and settlements related to Medicare and Medicaid programs. Recent federal actions and judicial considerations may alter the enforcement landscape of the FCA, directly impacting businesses interacting with government programs.
Regulatory Landscape
In July 2025, the Department of Justice (DOJ) and the Department of Health & Human Services (HHS) launched a specialized False Claims Act Working Group. Their objective is to enhance enforcement efforts across priority areas, emphasizing fraud prevention among healthcare providers, insurance carriers, and pharmaceutical companies involved with government healthcare initiatives. This strategic move highlights the industry-wide impact of regulatory compliance requirements.
The Working Group stresses the importance of reporting FCA violations and delineates between notifying HHS about potential fraud and initiating qui tam litigation. It outlines criteria for DOJ's possible dismissal of qui tam suits that lack alignment with government priorities, focusing on merit and administrative feasibility.
Judicial Scrutiny
The framework supporting the FCA's qui tam provisions, allowing private individuals—or relators—to sue on behalf of the government, is under judicial review. Courts are examining these provisions for constitutional compliance, particularly in relation to the Appointment and Take Care Clauses of Article II of the U.S. Constitution. Diverging judicial opinions have led to an ambiguous legal environment, questioning the validity of private enforcement actions.
District courts present mixed rulings on the constitutional standing of the FCA's private enforcement provisions. Legal professionals and industry stakeholders must closely monitor these evolving interpretations, as they bear significant implications for defense strategies in qui tam lawsuits.
Business Considerations
Insurers and other businesses operating within the scope of FCA enforcement face increased scrutiny regarding compliance and reporting practices. Enhanced risk management through robust internal controls could mitigate potential FCA-related violations, aligning operations with current regulatory standards.
Given the uncertain judicial landscape surrounding the FCA's qui tam provisions, businesses involved with federal programs should stay proactive. Keeping abreast of legislative changes will enable companies to adjust legal strategies and compliance frameworks effectively, ensuring regulatory alignment and reducing risk exposure.